# Appendix C Reporting proforma for carcinomas of the sinonasal tract

|  |  |  |
| --- | --- | --- |
| Surname………………… | Forenames…………………… | Date of birth………….... Sex.......  |
| Hospital………….……….  | Hospital no……………….…...  | NHS/CHI no……………..  |
| Date of receipt…………. | Date of reporting………..…...  | Report no……………......  |
| Pathologist……….… | Surgeon………………….…… |   |

**Neoadjuvant therapy**

Information not provided □ Not administered □

Administered □ specify type: Chemotherapy □ Radiotherapy □ Chemoradiotherapy □

Targeted therapy □ specify, if available ………………………………

Immunotherapy □ specify, if available ……………………………….

**Operative procedure (Core) (select all that apply):**

Not specified □

Resection: Open □ Endoscopic □ Combined □ En bloc □ Piecemeal □ specify..............................
Biopsy (excisional, incisional, core biopsy) □ specify *………………………*

Neck dissection □ specify *…………………………*

**Specimens submitted (Core) (select all that apply):**
Not specified □

Nasal cavity □ Left □ Right □ Laterality not specified □

Paranasal sinus □ specify............................. Left □ Right □ Laterality not specified □

Orbit □ specify............................. Left □ Right □ Laterality not specified □

Neck (lymph node levels) □ specify............................. Left □ Right □ Laterality not specified □

 Other □, specify ……………………………………….

**Tumour site** **(Core)** **(select all that apply)**

**Not specified □**

Nasal cavity **□**

Septum □

Floor □ Lateral wall □ Vestibule □

Left □ Right □ Laterality not specified □

Paranasal sinus **□**

Maxillary **□** Left □ Right □ Laterality not specified □

Ethmoid **□** Cribriform plate □

Orbit **□** Left □ Right □ Laterality not specified □

Cranial cavity □ specify …………………Left □ Right □ Laterality not specified □

Other: □ specify ………………………………………

**Tumour dimensions (Non Core)**

Maximum tumour dimension (largest tumour) …………….mm

Additional dimensions …………….mm

Cannot be assessed, specify …………………………

**Histological tumour type (Core)**

Multi selection value list (select all that apply):

Keratinising squamous cell carcinoma □

Other squamous cell carcinoma subtype, specify type …………………………

Non-keratinising squamous cell carcinoma □

NUT carcinoma □

SWI/SNF complex-deficient sinonasal carcinoma □

Sinonasal lymphoepithelial carcinoma □

Sinonasal undifferentiated carcinoma □

Teratocarcinosarcoma □

HPV-related multiphenotypic sinonasal carcinoma □

Neuroendocrine neoplasm □

Small cell neuroendocrine carcinoma □

Large cell neuroendocrine carcinoma □

Carcinoma mixed with neuroendocrine carcinoma □

Other (specify type) …………………………

Adenocarcinoma □

Intestinal-type adenocarcinoma □

Non-intestinal-type adenocarcinoma □

Salivary gland-type carcinoma □ specify type …………………………

**Histological tumour grade (Core)**

Not applicable □

Grade 1, well differentiated, low grade □

Grade 2, moderately differentiated, intermediate grade □

Grade 3, poorly differentiated, high grade □

Undifferentiated □

High grade transformation □

Grading system used, specify …………………………

Cannot be assessed, specify …………………………

(Use Grade 1, 2 and 3 only for neuroendocrine tumours; neuroendocrine carcinomas are considered high grade by definition and are therefore not graded).

**Extent of invasion**

Not identified □

Bone invasion □ / Cartilage invasion □ Erosive □ Infiltrative □

Cannot be assessed □ specify

Soft tissue infiltration □

Skull base involvement □

Invasion of skin □

Invasion of orbital tissues □

Other □ specify ………………**…**

Cannot be assessed □ specify reason …………………

**Lymphovascular invasion**

Not identified □

Present □

Indeterminate □ specify reason …………………

**Perineural invasion**

Not identified □

Present □

Indeterminate, specify reason …………………

**Margin status (Core)**

**Invasive carcinoma**

Involved □ specify location of margin(s) (if possible) ………………….

Not Involved □ Specify closest margins (if possible) ……………mm.

Cannot be assessed □ specify reason ……………….

**Precursor lesions**

Not applicable □

Not present □

Present (e.g., sinonasal papilloma (type), surface dysplasia), specify ……………….

**Ancillary studies**

Not performed □ Performed □

**Non-keratinising squamous cell carcinoma** □

Positive □ Pancytokeratin □ p40 □ p63 □ CK5/6 □ Others, specify ……………….

Negative □ CD99 □ NKX2.2 □ NUT □ Others, specify ……………….

If performed, specify (select) all that apply

INI1 □ Retained □ Deficient □ Not performed □

BRG1 □ Retained □ Deficient □ Not performed □

**NUT carcinoma**

Positive □

NUT immunohistochemistry □

NUTM1 gene rearrangement □, specify technique ……………….

**SWI/SNF complex-deficient sinonasal carcinoma**

INI1 Retained □ Deficient □

BRG1 Retained □ Deficient □

**Sinonasal undifferentiated carcinoma**

Positive □ Pancytokeratin □ CK7 □ IDH1/2 □

Negative □ p40/p63 □ CK5/6 □ CD99 □ NKX2.2 □ NUT □

INI1 Retained □ Deficient □

BRG1 Retained □ Deficient □

**HPV-related multiphenotypic sinonasal carcinoma**

Positive □ p16 immunohistochemistry (screening) □

Positive □ HPV-specific testing □ specify technique ………………........

**Neuroendocrine carcinoma**

Positive □ CAM5.2/CK-pan □ Synaptophysin □ Chromogranin □ INSM1 □

Ki-67 proliferation index □ specify …………%

Rb Retained □ Deficient □

**Keratinising squamous cell carcinoma**

Positive □ Pancytokeratin □ p40 □ p63 □ CK5/6 □

**Sinonasal lymphoepithelial carcinoma**

Positive □ Pancytokeratin □ p16 □ EBER in situ hybridisation □

**Teratocarcinosarcoma**

Positive □ Nuclear ß-catenin □

BRG1 (SMARCA4) Retained □ Deficient □

Intestinal type adenocarcinoma

Positive □ CK20 □ CDX2 □ SATB2 □ Villin □ CK7 □

Non-intestinal-type sinonasal adenocarcinoma

Positive □ CK7 □ SOX10 □ DOG1 □ Nuclear ß-catenin □

Negative □ CK20 □ CDX2 □

Other ancillary studies: ………………........

**Representative blocks for ancillary studies** (Best blocks with viable tumour and normal tissue): ………………........

**Pathological staging (Core) (UICC TNM 8th edition, only if applicable)**

pTNM stage pT......